InSure® FIT™ (marketed as ColoVantage Home outside the U.S.) is based on the latest technology to detect hidden bleeding that may indicate colorectal disease.
First released in 2000, InSure FIT is a fecal immunochemical test (FIT) that has now been used to screen millions of people around the world. InSure FIT addresses a number of issues related to colorectal disease detection:
- The test detects blood in the stool/feces (which is often hidden) that may be an early symptom of serious colorectal diseases.
- The patented ‘Brush’ sampling technology is used to test the water in a toilet bowl for hidden blood.
- The advanced chemistry of InSure FIT is specific for lower gastrointestinal bleeding.
- The test does not require changes to diet or medications.
- The InSure FIT Test Card uses patented technology to store the sample in a more stable, dry format for transportation to the lab for testing.
Clinical studies have proven that InSure FIT is highly accurate for detecting even tiny or invisible amounts of blood in a sample. The test has a very high sensitivity (88%) and an exceptional specificity to reduce the likelihood of false positives (96–98%).
Information for Medical Professionals
With nearly 150,000 cases identified each year, colorectal cancer remains one of the medical community’s greatest diagnostic challenges. When colorectal cancers are detected at an early, localized stage, the 5-year survival is 91%; however, only 39% of colorectal cancers are diagnosed at this stage, in part due to underuse of screening. After the cancer has spread regioinally to involve adjacent organs or lymph nodes, the 5-year survival drops to 70%. When the disease has spread to distant organs, the 5-year survival is 11%.1
To help improve colorectal cancer screening compliance, physicians should consider the InSure FIT screening test, which offers high sensitivity and ease of use:
- Patient-friendly, water-based collection method, and patented brush sampling replaces unpleasant fecal collection or smearing
- No dietary or medication restrictions
- The InSure FIT test had a 66% increase in patient compliance versus a guaiac-based fecal occult blood test (gFOBT) in one study.2
InSure FIT is a CLIA waived test available for laboratory services and in-office / Physician Office Lab (POL) testing. For laboratory services contact your Clinical Genomics sales representative. For in-office / Physician Office Lab (POL) testing contact one of our distributor partners or Enterix Inc. at 1-800-531-3681.
Order Insure FIT or Request Additional Information
- American Cancer Society. Cancer Facts and Figures, 2010, page 13.
- Cole SR, Young GP, Esterman A, Cadd A, Morcom J. A randomized trial of the impact of new faecal haemoglobin test technologies on population participation in screening for colorectal cancer. J Med Screen 2003;10:117-122.